Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios
Vertex pays $60 million upfront to license two nucleotide polymerase inhibitors it will test in combination therapy with other HCV assets in its pipeline.
Vertex pays $60 million upfront to license two nucleotide polymerase inhibitors it will test in combination therapy with other HCV assets in its pipeline.